NASDAQ : BBNX
Beta Bionics, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 17.58 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 955.77M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 910.65M |
| Enterprise Value | 676.55M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 54.37M |
| Shares Outstanding | 54.37M |
| Shares Change (YoY) | +44.45% |
| Shares Change (QoQ) | +4.48% |
| Owned by Insiders (%) | 1.94% |
| Owned by Institutions (%) | 100.46% |
| Float | 42.14M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.16 |
| Forward PS | 5.78 |
| PB Ratio | 2.27 |
| P/TBV Ratio | 2.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.92 |
| Quick Ratio | 8.04 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -23.88% |
| Return on Assets (ROA) | -14.96% |
| Return on Invested Capital (ROIC) | -16.30% |
| Return on Capital Employed (ROCE) | -22.53% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $300,863 |
| Profits Per Employee | -$196,494 |
| Employee Count | 423 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 2.43 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | -37.48% |
| 50-Day Moving Average | 19.11 |
| 200-Day Moving Average | 14.82 |
| Relative Strength Index (RSI) | 41.51 |
| Average Volume (20 Days) | 1,141,166 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.92M |
| Short Previous Month | 6.05M |
| Short % of Shares Out | 12.72% |
| Short % of Float | 16.41% |
| Short Ratio (days to cover) | 4.82 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 127.27M |
| Gross Profit | 74.61M |
| Operating Income | -92.58M |
| Pretax Income | -83.12M |
| Net Income | -83.12M |
| EBITDA | -89.86M |
| EBIT | -92.58M |
| Loss Per Share | -$1.85 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 240.20M |
| Total Debt | 6.10M |
| Net Cash | 234.10M |
| Net Cash Per Share | $4.31 |
| Equity (Book Value) | 401.38M |
| Book Value Per Share | 7.38 |
| Working Capital | 260.11M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -59.37M |
| Capital Expenditures | -6.59M |
| Depreciation & Amortization | 2.72M |
| Net Borrowing | n/a |
| Free Cash Flow | -65.96M |
| FCF Per Share | -$1.21 |
Margins
| Measure | Value |
|---|
| Gross Margin | 58.63% |
| Operating Margin | -72.75% |
| Pretax Margin | -65.31% |
| Profit Margin | -65.31% |
| EBITDA Margin | -70.61% |
| EBIT Margin | -72.75% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -44.45% |
| Shareholder Yield | -44.45% |
| Earnings Yield | -11.03% |
| FCF Yield | -7.24% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $25.10 |
| Price Target Difference | 49.85% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 41.15% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 10.25 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |